The effectiveness of B-cells in chemotherapy and its potential for treatment

Tumor microenvironment (TME) has been regarded as a critical regulating environment for immune response and tumor growth in recent years. Similar to the interaction between seeds and soil, TME actively supports the progression of cancer rather than acting as a passive spectator. The anti-tumor and pro-tumor actions of B cells in TME have generated a lot of discussion, and they have the potential to be a predictive biomarker of treatment response. Chemotherapy modifies anti-tumor immunity and therapeutic effects by altering the quantity and activity of B lymphocytes in the TME. B cells are a new and important component in the therapy of cancer, and their therapeutic potential merits more research. To shed light on the possible role of B cells in chemotherapy, a group of Chinese commentators summarized clinical trials of B cell-related targets and described how chemotherapy affects different B cell subtypes and how they interact within the TME in a study published in the journal Clinical and Translational Medicine.

The group discovered that chemotherapy can change the distribution and function of subpopulations, including cytokine release, receptor signaling, and the expression of co-stimulatory molecules, in addition to inhibiting B cell growth. Additionally, B cells have the ability to regulate T cell responses when chemotherapy is present. Chemotherapy can promote anti-tumor immunity by causing B cells to suppress Tregs and activate T cells. We continue to concentrate on B cell-related targets in order to investigate the therapeutic potential of B cells. We continue to concentrate on B cell-related targets in order to investigate the therapeutic potential of B cells. It has been demonstrated that targeting B-cell surface markers or signaling pathways enhances the effects of chemotherapy, stops immune evasion, and slows tumor growth. In addition to directly influencing B cell activity, targeting tumor cells or macrophages can boost anti-tumor immunity, stop tumor development, and increase the effectiveness of chemotherapy.

According to Peng Luo, the researcher who led the study, "Although we are pleased to see the increasing widespread research on B cells in the TME, it is undeniable that there are still key knowledge gaps in B cell interactions within the TME, B cell chemotherapy resistance mechanisms, tertiary lymphoid structural biology, heterogeneity and spatial distribution, chemotherapy drug selection, B cell-related targets, etc.." He continued, "We look forward to seeing more in-depth research reported in the future, which will help B cells realize greater potential in tumor chemotherapy and combination treatment options."